Mobilisation of Emergency funding for Mpox outbreak research response
This program, the 'Mobilisation of Emergency funding for Mpox outbreak research response', rapidly addresses the Public Health Emergency caused by the Mpox outbreak, particularly in the Democratic Republic of Congo (DRC). It aims to generate critical, timely research insights into Mpox management and prevention, with a specific focus on vulnerable populations such as children, pregnant women, and immunosuppressed individuals, while strengthening research capacities in at-risk countries.
Who is Funded
This program supports research efforts aimed at addressing the Mpox public health emergency. Funding is available for specific legal entities and collaborations within defined geographic areas, with the overarching goal of generating new knowledge for effective disease management and prevention.
What is Funded
This funding program focuses on research and innovation actions aimed at addressing the Mpox public health emergency. Supported activities span vaccine development, clinical trials for therapeutics, and enhanced surveillance with rapid diagnostics, primarily through applied research and experimental development stages.
Type and Scope of Funding
The program provides grant funding, with a maximum allocation per project. While specific project durations are not detailed, the emphasis is on rapid activation and timely outcomes.
Conditions and Requirements
Applicants and beneficiaries must adhere to strict conditions regarding application, consortium composition, budget management, and the exploitation of results. These conditions ensure ethical research, data sharing, and broad access to health technologies.
Application Procedure
The application process was streamlined and operated on a fast-track basis, with a short opening period. Proposals were evaluated based on specific criteria, and grants were awarded not only by ranking but also considering the overall portfolio quality.
Legal Basis
The program is fundamentally governed by comprehensive EU regulations and work programs, ensuring its legitimacy, operational framework, and adherence to financial and ethical standards.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
1,250,000 €
Allocated Budget:
6,500,000 EUR
Award Channel:
Framework Programme Call
Region:
Democratic Republic of Congo (DRC) and neighbouring or affected countries. Eligible countries for participation include EU Member States (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden), their Overseas Countries and Territories (OCTs), countries associated with Horizon Europe (e.g., Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, New Zealand, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine, United Kingdom, Canada, Morocco), and constituent states of the EDCTP Association in Sub-Saharan Africa (e.g., Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe).
Sectors:
Healthcare, Research and Development
Beneficiaries:
Children, pregnant women, and immunosuppressed individuals most affected by Mpox.
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development
Funding Provider
Program Level:
European Union
Funding Body:
Global Health EDCTP3 Joint Undertaking (JU)
Additional Partners:
Partnerships with researchers and public health institutions in DRC and neighbouring countries, and coordination with other research and/or humanitarian activities operational in affected countries are encouraged. Alignment with Africa CDC Task Force recommendations is also expected.
Website: